Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $20.60

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.60.

Several analysts have weighed in on KPTI shares. Piper Sandler restated an “overweight” rating and issued a $12.00 target price (down from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. HC Wainwright cut shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 16th. Finally, Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $56,000. Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics during the second quarter worth $163,000. Silverback Asset Management LLC raised its holdings in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after buying an additional 20,000 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in Karyopharm Therapeutics by 60.3% during the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock worth $93,000 after buying an additional 51,856 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $5.50 on Friday. The firm has a 50-day moving average of $6.00 and a 200-day moving average of $5.17. The stock has a market cap of $47.69 million, a PE ratio of -0.38 and a beta of 0.34. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).